Disease · MONDO_0023644

lip and oral cavity carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. lip and oral cavity carcinoma. Diseases, record MONDO_0023644. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0023644

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: lip and oral cavity carcinoma; Open Targets
Open Targets ID: MONDO_0023644; Open Targets
Other names: lip and oral cavity cancer, oral cancer, oral carcinoma; Open Targets
NCI Thesaurus: C9315; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 1 of its 19 drugs, from TTD; Open Targets

Drugs19

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CONTUSUGENE LADENOVEC	CHEMBL2108585	Gene	Phase 3	TTD	1	0	0	Drugs and targets
AMINOLEVULINIC ACID	CHEMBL601	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
HYDROXYUREA	CHEMBL467	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
METRONIDAZOLE	CHEMBL137	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CALCITRIOL	CHEMBL846	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
CELECOXIB	CHEMBL118	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
ENILURACIL	CHEMBL355200	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 19

See all 19 drugs

Targets29

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	2	Programmed cell death protein 1 inhibitor	Phase 1	https://conductscience.org/library/genes/5133	Drugs and targets
CCR4	C-C chemokine receptor type 4	1	C-C chemokine receptor type 4 cross-linking agent	Phase 1	https://conductscience.org/library/genes/1233	Drugs and targets
DPYD	Dihydropyrimidine dehydrogenase [NADP(+)]	1	Dihydropyrimidine dehydrogenase inhibitor	Phase 1/2	https://conductscience.org/library/genes/1806	Drugs and targets
DRD2	D(2) dopamine receptor	1	Dopamine D2 receptor antagonist	Unknown	https://conductscience.org/library/genes/1813	Drugs and targets
EGFR	Epidermal growth factor receptor	1	Epidermal growth factor receptor erbB1 inhibitor	Unknown	https://conductscience.org/library/genes/1956	Drugs and targets
HTR3A	5-hydroxytryptamine receptor 3A	1	Serotonin 3a (5-HT3a) receptor antagonist	Unknown	https://conductscience.org/library/genes/3359	Drugs and targets
HTR4	5-hydroxytryptamine receptor 4	1	Serotonin 4 (5-HT4) receptor agonist	Unknown	https://conductscience.org/library/genes/3360	Drugs and targets
PTGS2	Prostaglandin G/H synthase 2	1	Cyclooxygenase-2 inhibitor	Phase 1/2	https://conductscience.org/library/genes/5743	Drugs and targets
RRM1	Ribonucleoside-diphosphate reductase RR1	1	Ribonucleoside-diphosphate reductase RR1 inhibitor	Phase 2	https://conductscience.org/library/genes/6240	Drugs and targets
RRM2	Ribonucleoside-diphosphate reductase RR1	1	Ribonucleoside-diphosphate reductase RR1 inhibitor	Phase 2	https://conductscience.org/library/genes/6241	Drugs and targets

1 to 10 of 29

See all 29 targets

Trials12

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03638622	Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.	Phase 1/2	30	2021-02-21	Oral Cancer	AMINOLEVULINIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00953849	Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity	Phase 1/2	21	2016-12-21	Mouth Neoplasms	CALCITRIOL, CELECOXIB	Its record names the disease	ClinicalTrials.gov
NCT06876038	Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions	Phase 2	65		Oral Cancer, Oral Cavity Cancer, Oral Leukoplakia, Oral Lichen Planus, Oral Squamous Cell Carcinoma	AMINOLEVULINIC ACID	Its record names the disease	ClinicalTrials.gov
NCT07082621	N Acetylcystene in Treatment of Radiotherapy Induced Oral Mucositis in Oral Cancer Patients	Not applicable	40		Oral Mucositis	ACETYLCYSTEINE	Its record names the disease	ClinicalTrials.gov
NCT07015333	Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab		31		Oral Squamous Cell Carcinoma (OSCC)	CETUXIMAB, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT06627270	Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer	Phase 2	30		Oral Squamous Cell Carcinoma, Oral Cancer, Head and Neck Cancer, Head and Neck Carcinoma	METRONIDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03934294	Acupuncture Effect on Digestion in Critically Ill Post-Operative Oral and Hypo-pharyngeal Cancer Patients	Not applicable	28		Oral Cancer, Hypopharyngeal Cancer	METOCLOPRAMIDE	Its record names the disease	ClinicalTrials.gov
NCT05308732	Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy	Phase 1	20		Head and Neck Neoplasms, Mucositis Oral, Radiotherapy; Complications	CISPLATIN, FLUCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03843515	Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction	Phase 1	17		Oral Cavity Squamous Cell Carcinoma	NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT02946671	Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients	Phase 1	16		Gastric Cancer, Esophageal Cancer, Lung Cancer, Renal Cancer, Oral Cancer	MOGAMULIZUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 12

See all 12 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41862922	DERIVED	1	PubMed
40180420	DERIVED	1	PubMed
35367616	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0023644

GET https://conductscience.org/api/diseases/v1/MONDO_0023644/targets?page=2

API reference For AI assistants